Tirzepatide

Tirzepatide

Tirzepatide (Mounjaro, Zepbound)

Dual GLP-1/GIP agonist — stronger than Semaglutide

Fat Loss ★ 96 FDA Approved
Half-life
~5 days
Cycle
Not cycled. Long-term use with taper if discontinuing.
Storage
Refrigerated 2-8°C. Compounded: 30-56 days after reconstitution.
Research
FDA approved (Mounjaro 2022, Zepbound 2023)

About

A dual agonist that activates both GLP-1 and GIP receptors. FDA approved 2022. Shows 20-22% weight loss in clinical trials.

Mechanism

Activates both GLP-1 and GIP, producing synergistic effects on glycemic control, insulin sensitivity, and adipose-tissue regulation.

Dosage

2.5 mg
1x per week for 4 weeks
0102030405060708090100

Draw to 50 units on a U-100 insulin syringe

10 mg · 2 mL BAC

Route
SubQ
Duration
Titration phase

When to take: Same day each week. Any time of day, with or without food.

Reconstitution

Vial size (mg): 10 mg · BAC water (mL): 2 mL · Concentration: 5 mg/mL

Compounded version. Prescription pen is pre-filled.

Benefits

  • 20-22% weight loss (SURMOUNT trials)
  • Stronger effects than Semaglutide (head-to-head trial)
  • Improved glycemic control
  • Lowered blood pressure
  • Improved lipid profile

Side effects

  • Nausea (common initially)
  • Diarrhea
  • Reflux
  • Constipation
  • Abdominal pain

Gender notes

Same dose. Sometimes more pronounced weight loss than in women.

Cautions

  • Medullary thyroid carcinoma
  • MEN 2 syndrome
  • Pregnancy
  • History of pancreatitis
  • Severe gastrointestinal disease

Research

Stacks well with

BPC-157Ipamorelin
Add reminder Calculator